Table 2 Cox proportional hazards regression analysis of progression-free survival.

From: Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

  

HR (95% CI)

P-value

Age (years)

 > 65 years vs. < 65 years

1.09 (0.63–1.87)

0.759

Sex

Male vs. Female

0.99 (0.63–1.55)

0.963

Brain metastasis

Presence vs. Absence

1.69 (1.06–2.70)

0.028

Performance status

ECOG ≥ 2 vs. 0–1

1.66 (0.85–3.25)

0.138

EGFR mutation

Exon 19 deletion vs. Others

0.97 (0.60–1.57)

0.908

PD-L1 level

 ≥ 50% vs. < 1%

1.42 (0.73–2.76)

0.300

1–49% vs. < 1%

1.17 (0.68–2.01)

0.576

E-cadherin

Loss vs. preserved

1.33 (0.69–2.56)

0.393

MET

Presence vs. absence

1.00 (0.62–1.62)

0.989

p-STAT3

Presence vs. absence

0.78 (0.48–1.29)

0.337

p-AKT

Presence vs. absence

1.08 (0.64–1.83)

0.767

BIM

Presence vs. absence

2.94 (1.41–6.14)

0.004

  1. EGFR, epidermal growth factor receptor.
Back to article page